This consideration is particularly critical, as amyloid precursor protein (APP)–targeting small interfering RNA (siRNA) therapeutics are currently undergoing clinical evaluation for the treatment of AD and cerebral amyloid angiopathy (CAA).37 The gene discussed is APP; the disease is cerebral amyloid angiopathy.